Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

5.4K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
5.4K
Cancer Vaccines01:30

Cancer Vaccines

509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linking deubiquitination to pyroptosis: new perspectives from OTUB1 in hepatocellular carcinoma.

Journal of gastrointestinal oncology·2026
Same author

Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.

Cancer letters·2026
Same author

Discovery of New OTUB1 Covalent Ligands via Structure-Activity Relationship Studies for Targeted Protein Stabilization.

Journal of medicinal chemistry·2026
Same author

Aberrant amino acid-sensing promotes immunotherapy resistance via the inflammatory cytokine-ZBTB5-mTORC1 axis.

Nature cell biology·2026
Same author

Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.

Signal transduction and targeted therapy·2026
Same author

Endocytic Adaptor Proteins in Vascular Diseases: Critical Role of Intracellular Trafficking in Regulating Pathobiology of Vascular Disorders.

Cardiology discovery·2026

Related Experiment Video

Updated: Sep 8, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

PROTAC technology for prostate cancer treatment.

Zhen Wang1, Dingpeng Zhang1, Hiroyuki Inuzuka1

  • 1Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

Acta Materia Medica
|August 20, 2025
PubMed
Summary

Prostate cancer (PrCa) is a common male cancer. This review covers PrCa biomarkers and new castration-resistant PrCa (CRPC) treatments, highlighting Proteolysis-targeting chimeras (PROTACs) for combating resistance.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.0K

Related Experiment Videos

Last Updated: Sep 8, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.0K

Area of Science:

  • Oncology
  • Urology
  • Molecular Biology

Background:

  • Prostate cancer (PrCa) is the most common male urogenital cancer, with metastatic spread causing mortality.
  • Key drivers of PrCa progression include genetic mutations, androgen receptor (AR) signaling, and AR splice variants.
  • Androgen deprivation therapy (ADT) is standard for early PrCa but often leads to castration-resistant PrCa (CRPC).

Purpose of the Study:

  • To review critical biomarkers for prostate cancer detection and monitoring.
  • To explore emerging therapeutic strategies for castration-resistant prostate cancer (CRPC).
  • To highlight the potential of Proteolysis-targeting chimera (PROTAC) technology in overcoming CRPC resistance mechanisms.

Main Methods:

  • Literature review of prostate cancer progression and treatment resistance.
  • Analysis of current and investigational therapies for CRPC.
  • Exploration of the mechanism and application of PROTAC technology in cancer therapy.

Main Results:

  • Identified key genetic and molecular factors contributing to PrCa progression and resistance to ADT.
  • Summarized established and novel therapeutic targets for CRPC.
  • Detailed the mechanism of PROTACs in targeted protein degradation and their potential efficacy against CRPC.

Conclusions:

  • Prostate cancer necessitates continuous research into effective biomarkers and treatment strategies.
  • CRPC remains a significant clinical challenge, requiring innovative therapeutic approaches.
  • PROTAC technology presents a promising avenue for developing next-generation therapies to overcome treatment resistance in CRPC.